GLP-1 receptor modulators, initially developed for diabetes, have emerged as effective weight loss therapies inducing 15-20% body weight reduction. Experts emphasize their use in conjunction with lifestyle changes to sustain results. However, supply chain strains have raised ethical questions about drug allocation between diabetes and obesity patients, while counterfeit markets pose safety risks. These developments highlight the rapid transformation in obesity management and the complexities around access and regulation.